20 articles
Scientists used red blood cells to transport healthy mitochondria into diseased brain cells, showing promise for Parkinson's treatment.
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
FORZINITY becomes the first FDA-approved therapy targeting mitochondria directly, launching for Barth syndrome patients amid a company rebrand.
Duke researchers restored healthy mitochondria to damaged nerve cells, cutting pain-related behaviors by 50% in mice with nerve pain.
Yale researchers solved how coenzyme A from vitamin B5 enters mitochondria, unlocking new insights into metabolism and disease prevention.
Scientists find declining phosphatidylcholine disrupts mitochondria with age — and replenishing it quickly restores youthful cell energy.
Scientists find phosphatidylcholine loss fragments mitochondrial networks with age — and supplementing it may help reverse the damage.
University of Cologne researchers reveal how the amino acid leucine boosts cellular energy by preventing breakdown of critical mitochondrial proteins.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
UK biotech secures MJFF grant to tackle GBA1 mutations — the most common genetic risk factor for Parkinson's — with a novel two-protein approach.
MitoRx's MTRX31 targets mitochondrial metabolism to slash fat mass 62% in mice while preserving muscle — no hunger suppression needed.
Rafael Holdings licenses MIT patent for cyclodextrin therapy targeting cholesterol transport failure in ApoE4-linked Alzheimer's disease.
NADMED funds groundbreaking research on metabolic assessment of donor organs, advancing redox biology toward real-world longevity medicine.
A new grant-funded program aims to develop the first disease-modifying treatment for the most common genetic form of Parkinson's disease.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
Rafael Holdings secures exclusive MIT patent rights for cyclodextrins in ApoE4-positive Alzheimer's patients, a group representing up to 70% of cases.
SonoThera raises $125M to advance ultrasound-based gene delivery that bypasses viral limits, enabling repeat dosing critical for longevity therapies.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
A single FGF21 gene injection in aging mice extended median lifespan by 20%, reversing fat gain, inflammation, and organ decline.
University of Rochester scientists moved a longevity gene from naked mole rats into mice, boosting lifespan 4.4% and cutting cancer risk.
